Compare GRRR & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GRRR | FDMT |
|---|---|---|
| Founded | 2001 | 2013 |
| Country | United Kingdom | United States |
| Employees | 200 | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 419.5M | 479.9M |
| IPO Year | N/A | 2019 |
| Metric | GRRR | FDMT |
|---|---|---|
| Price | $13.43 | $10.36 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $31.71 |
| AVG Volume (30 Days) | ★ 780.3K | 645.5K |
| Earning Date | 06-17-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 18.79 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $85,209,000.00 |
| Revenue This Year | $69.35 | N/A |
| Revenue Next Year | $85.38 | $70.28 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 230194.60 |
| 52 Week Low | $9.04 | $3.03 |
| 52 Week High | $27.90 | $12.34 |
| Indicator | GRRR | FDMT |
|---|---|---|
| Relative Strength Index (RSI) | 50.13 | 57.13 |
| Support Level | $12.13 | $9.71 |
| Resistance Level | $15.83 | $10.70 |
| Average True Range (ATR) | 0.86 | 0.58 |
| MACD | -0.14 | 0.09 |
| Stochastic Oscillator | 33.39 | 64.98 |
Gorilla Technology Group Inc is engaged in providing information, software, and data processing services. It is a provider of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology (OT) security solutions and services. Its reportable segments are video IoT and security convergence and Other segments. Its expertise lies in revolutionizing urban operations, enhancing security, and optimizing digital transformation. It delivers pioneering products that integrate AI, deep learning, and edge computing to advance intelligent video surveillance, facial recognition, license plate recognition, post-event analytics, cybersecurity, and network intelligence.
4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Companies focus is on advancing 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) through late-stage studies. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).